ALZpath Broadens Strategic Agreement with Alamar Biosciences to Advance Clinical Diagnostics for Alzheimer's Disease
Expanded collaboration grants Alamar commercial rights to utilize ALZpath's proprietary pTau217 antibody in blood-based diagnostic tests for clinical use CARLSBAD, Calif., July 23, 2026 /PRNewswire/ -- ALZpath, Inc., a leader in blood test-based diagnostic solutions for Alzheimer's...
Expanded collaboration grants Alamar commercial rights to utilize ALZpath's proprietary pTau217 antibody in blood-based diagnostic tests for clinical use CARLSBAD, Calif., July 23, 2026 /PRNewswire/ -- ALZpath, Inc., a leader in blood test-based diagnostic solutions for Alzheimer's...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.